Drugmakers in the red, as CMS releases its drugs that are subject to medicare price negotiations. The names getting hit the hardest, and how its impacting the weight loss drug race. Plus Is Intel on the market? M&A rumors helping boost the stock, but who could be the buyer? What a deal could mean for the beaten down chipmaker, and the impact on the tech space.

Fast Money Disclaimer

Apple’s decline continues as iPhone sales in China plunge for its worst yearly decline ever. And with tariffs dangling overhead, could there be even more trouble ahead for the tech giant. Plus A Bitcoin Bond ETF the latest addition to the crypto craze. What it is, and how proxies like MicroStrategy play a role in its performance.

Fast Money Disclaimer

Bank stocks surging as the group kicks off earnings season on a positive note. How their financials are faring, and the setup for the rest of earnings. And It wasn’t just the banks in the green. Stocks surging across the board as core inflation slows in December. What the data means for the central bank’s next move, as we count down to another Fed rate decision.

Fast Money Disclaimer

Shares of Eli Lilly taking a hit, as the pharma giant cuts its sales outlook. But could the dip be a buying opportunity? The latest out of JP Morgan’s Health Care Conference in San Francisco. And speaking of JP Morgan… the big bank and its peers kicking off earnings season tomorrow. What to expect from those results and why one top bank analyst says it’s all about the yield curve for the group.

Fast Money Disclaimer

Some of the most popular names in the market seeing some major moves. How the recent drops in Nvidia, Tesla, and Bitcoin fare from here, and how banks are setting up ahead of earnings season. Plus The prognosis on the health care space, as the industry’s top execs convene at the JPMorgan conference in San Francisco. How our traders are handling the moves in the space’s biggest names.

Fast Money Disclaimer

Stocks selling off as investors digested this morning’s stronger than expected jobs report. And with nearly all of the post-election gains fading, with next week’s inflation data cause even more volatility? Plus Obesity drugs expected to be in focus at this year’s JPMorgan Health Care conference. How the industry’s biggest names are handling competition, and the next-generation of weight loss drugs.

Fast Money Disclaimer

Rates on the rise, as investors brace for what President-elect Donald Trump’s tariff plan could do to inflation. The trouble brewing under the surface.. And the sections of the market feeling the pressure. And A check on the middle market. What a new report out of a private credit powerhouse is saying about the landscape.

Fast Money Disclaimer

Meta scrapping its third-party fact-checking program, as the social giant moves closer towards an ‘X’ style platform. Why CEO Mark Zuckerberg is calling the recent election a ‘tipping point’ for the move, and how users will respond to the changes. Plus From Leaders to laggards. Why Katie Stockton sees big opportunity in some beaten down spaces as a rotation gets underway. 

Fast Money Disclaimer

Shares of Nvidia closing at a record high, as CEO Jensen Huang gets ready to take the stage at the Consumer Electronics Show in Las Vegas. What he’ll say about the company’s next move, and if this stock can keep hitting records. Plus President-elect Donald Trump reportedly changing his tune on tariffs. The stocks seeing the biggest impact, and the inflation risk that comes with a universal tariff.

Fast Money Disclaimer

Markets closing out the week with a bang, as the S&P 500 and Nasdaq snap 5 day losing streaks. What the start of January could say about 2025 trading, and the latest comments from one Federal governor. Plus China targeting dozens of U.S. companies with new sanctions.The impact on markets, and what it means for U.S.-China relations.

Fast Money Disclaimer